ANTI — Antigenics Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual cashflow statement for Antigenics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
1996 December 31st | 1997 December 31st | 1998 December 31st | 1999 December 31st | 2000 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K405 | 10-K405 | 10-K405 | 10-K |
| Standards: | — | — | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.03 | -17 | -18.2 | -14.1 | -18 |
| Depreciation | |||||
| Non-Cash Items | 0.808 | 3.78 | 1.35 | 2.52 | -1.83 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.31 | 1.38 | 3.85 | -2.12 | 0.955 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7.59 | -10.7 | -12.2 | -13.1 | -18.3 |
| Capital Expenditures | -0.256 | -0.352 | -1.96 | -0.377 | -0.401 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -33 | 8.85 | 19.4 | 0.328 | 7.91 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -33.2 | 8.5 | 17.4 | -0.049 | 7.51 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 37.2 | 0.043 | 4.1 | 13.3 | 7.48 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.6 | -2.15 | 9.31 | 0.19 | -3.27 |